The MHC class I‐LILRB1 signalling axis as a promising target in cancer therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The MHC class I‐LILRB1 signalling axis as a promising target in cancer therapy

Published:2019-07-23 Issue:5 Volume:90 Page:
ISSN:0300-9475
Container-title:Scandinavian Journal of Immunology
language:en
Short-container-title:Scand J Immunol

Author:

Zhao Jinming¹²,Zhong Shanshan³,Niu Xing⁴,Jiang Jiwei³,Zhang Ruochen⁵,Li Qingchang¹²^ORCID

Affiliation:

1. Department of Pathology College of Basic Medical Sciences, China Medical University Shenyang Liaoning Province China

2. Department of Pathology First Affiliated Hospital of China Medical University Shenyang Liaoning Province China

3. Department of Neurology First Affiliated Hospital of China Medical University Shenyang Liaoning Province China

4. Second Clinical College China Medical University Shenyang Liaoning Province China

5. Yale School of Public Health Yale University New Haven Connecticut USA

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Immunology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/sji.12804

Reference90 articles.

1. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

2. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors

3. Immuno-oncologists eye up macrophage targets

4. New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape

5. SIRPA-Inhibited, Marrow-Derived Macrophages Engorge, Accumulate, and Differentiate in Antibody-Targeted Regression of Solid Tumors

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modulating macrophage-mediated programmed cell removal: An attractive strategy for cancer therapy;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

2. Brain macrophage senescence in glioma;Seminars in Cancer Biology;2024-09

3. “Find Me” and “Eat Me” signals: tools to drive phagocytic processes for modulating antitumor immunity;Cancer Communications;2024-06-23

4. MHC1/LILRB1 axis as an innate immune checkpoint for cancer therapy;Frontiers in Immunology;2024-06-07

5. From mechanism to therapy: the journey of CD24 in cancer;Frontiers in Immunology;2024-05-31

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3